90 related articles for article (PubMed ID: 33952479)
1. Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma.
Matsumoto J; Kotera Y; Watari S; Takeuchi K; Ueki H; Koyama T; Wada K; Fujiyoshi M; Nasu Y; Ariyoshi N
Anticancer Res; 2021 May; 41(5):2511-2521. PubMed ID: 33952479
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
5. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
[TBL] [Abstract][Full Text] [Related]
6. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
7. The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma.
Qixing M; Juqing X; Yajing W; Gaochao D; Wenjie X; Run S; Anpeng W; Lin X; Feng J; Jun W
Tumour Biol; 2017 Apr; 39(4):1010428317698340. PubMed ID: 28381170
[TBL] [Abstract][Full Text] [Related]
8.
Yamamoto Y; Nakase H; Matsuura M; Maruyama S; Masuda S
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32570960
[TBL] [Abstract][Full Text] [Related]
9. CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
Suzuki Y; Fujioka T; Sato F; Matsumoto K; Muraya N; Tanaka R; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
Br J Clin Pharmacol; 2015 Dec; 80(6):1421-8. PubMed ID: 26773964
[TBL] [Abstract][Full Text] [Related]
10. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
Rodríguez-Jiménez C; García-Saiz M; Pérez-Tamajón L; Salido E; Torres A
Drug Metab Pers Ther; 2017 Mar; 32(1):49-58. PubMed ID: 28245187
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
12. [Expression of CYP3A5 mRNA in children with acute leukemia].
Huang Z; Chai YH; Cen JN; He HL; Li J
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jul; 11(7):549-54. PubMed ID: 19650988
[TBL] [Abstract][Full Text] [Related]
13. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
14. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
15. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
[TBL] [Abstract][Full Text] [Related]
16. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
17. Impact of Sulfatase-2 on cancer progression and prognosis in patients with renal cell carcinoma.
Kumagai S; Ishibashi K; Kataoka M; Oguro T; Kiko Y; Yanagida T; Aikawa K; Kojima Y
Cancer Sci; 2016 Nov; 107(11):1632-1641. PubMed ID: 27589337
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3.
Ito A; Okada Y; Hashita T; Aomori T; Hiromura K; Nojima Y; Nakamura T; Araki T; Yamamoto K
Biochem Genet; 2017 Jun; 55(3):268-277. PubMed ID: 28324194
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
